Does each RSU granted by MPLT represent a share of common stock?

Yes. Each RSU granted to the Chief Medical Officer represents a contingent right to receive one share of MPLT voting common stock. Delivery of shares occurs as the RSUs vest over the defined schedule, assuming continued service.

MapLight Therapeutics (MPLT) grants CMO 54K options, 13K RSUs

Q: What is the vesting schedule for the RSUs granted by MPLT to Erin Pennock Foff?

The RSU award of 13,360 shares vests 1/4 on July 1, 2027 , with 1/16 vesting on each October 1, January 1, April 1, and July 1 thereafter. Vesting requires the executive’s continued service on each vesting date.

Q: How do the stock options granted to MPLT’s Chief Medical Officer vest?

The option covering 54,240 shares vests 1/4 on July 1, 2027 , then 1/48 monthly thereafter on the same calendar day. Continued service is required for each vesting installment before the August 16, 2036 expiration.

Q: What is the exercise price and expiration date of the new MPLT stock options?

The employee stock option has an exercise price of $11.245 per share and expires on August 16, 2036 . The option vests over four years starting July 1, 2027, subject to the executive’s continued service.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. (MPLT) reported equity compensation awards to its Chief Medical Officer, Erin Pennock Foff. She received an option for 54,240 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036, and a restricted stock unit award covering 13,360 shares. Both awards vest over time subject to continued service, and following these grants she directly holds 312,261 shares of voting common stock.

Insider Trade Summary

Net Buyer: 13,360 shares

Net Buy 2 txns

Insider Foff Erin Pennock

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) ^F3	54,240	$0.00	$0.00
Grant/Award	Voting Common Stock ^{F1, F2}	13,360	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 54,240 shares (Direct); Voting Common Stock — 312,261 shares (Direct)

Footnotes (3)

F1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
F2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3. 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Option shares granted: 54,240 shares Option exercise price: $11.245 per share Option expiration date: August 16, 2036 +4 more

7 metrics

Option shares granted 54,240 shares Employee stock option grant on August 17, 2026

Option exercise price $11.245 per share Exercise price for employee stock option granted

Option expiration date August 16, 2036 Expiration of employee stock option

RSU shares granted 13,360 shares Restricted stock unit award on August 17, 2026

Shares held after RSU grant 312,261 shares Direct voting common stock holdings following RSU acquisition

Initial RSU vesting date July 1, 2027 1/4 of RSUs vest on this date

Initial option vesting date July 1, 2027 1/4 of option shares vest on this date

Key Terms

restricted stock unit ("RSU"), Employee Stock Option, vesting, voting common stock

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest"

Employee Stock Option financial

"Employee Stock Option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

vesting financial

"1/4th of the RSUs shall vest on July 1, 2027, and 1/16th"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

voting common stock financial

"Each RSU represents a contingent right to receive one share of voting common stock"

FAQ

What equity awards did MapLight Therapeutics (MPLT) grant to its Chief Medical Officer?

MapLight Therapeutics granted its Chief Medical Officer an option for 54,240 shares at $11.245 per share and an RSU award for 13,360 shares. These awards vest over multiple years, contingent on continued service.

What is the vesting schedule for the RSUs granted by MPLT to Erin Pennock Foff?

The RSU award of 13,360 shares vests 1/4 on July 1, 2027, with 1/16 vesting on each October 1, January 1, April 1, and July 1 thereafter. Vesting requires the executive’s continued service on each vesting date.

How do the stock options granted to MPLT’s Chief Medical Officer vest?

The option covering 54,240 shares vests 1/4 on July 1, 2027, then 1/48 monthly thereafter on the same calendar day. Continued service is required for each vesting installment before the August 16, 2036 expiration.

What is the exercise price and expiration date of the new MPLT stock options?

The employee stock option has an exercise price of $11.245 per share and expires on August 16, 2036. The option vests over four years starting July 1, 2027, subject to the executive’s continued service.

How many MPLT shares does Erin Pennock Foff hold after these transactions?

After the reported RSU grant, Erin Pennock Foff directly holds 312,261 shares of voting common stock. The RSUs and options represent additional contingent or exercisable rights, each tied to specified vesting schedules and continued service conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 06:35 PM Accepted by SEC EDGAR 08/19/2026 - 06:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foff Erin Pennock

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	08/17/2026		A		13,360⁽¹⁾	A	$0⁽²⁾	312,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$11.245	08/17/2026		A		54,240		⁽³⁾	08/16/2036	Voting Common Stock	54,240	$0	54,240	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR